Larimar Therapeutics Inc (LRMR) - Total Assets
Based on the latest financial reports, Larimar Therapeutics Inc (LRMR) holds total assets worth $208.51 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Larimar Therapeutics Inc debt service capacity to assess how comfortably operating cash covers total debt obligations.
Larimar Therapeutics Inc - Total Assets Trend (2012–2025)
This chart illustrates how Larimar Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See net assets of Larimar Therapeutics Inc for net asset value and shareholders' equity analysis.
Larimar Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Larimar Therapeutics Inc's total assets of $208.51 Million consist of 97.4% current assets and 2.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 58.6% |
| Accounts Receivable | $747.00K | 0.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Larimar Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Larimar Therapeutics Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Larimar Therapeutics Inc's current assets represent 97.4% of total assets in 2025, an increase from 94.0% in 2012.
- Cash Position: Cash and equivalents constituted 58.6% of total assets in 2025, down from 90.4% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 0.5% of total assets.
Larimar Therapeutics Inc Competitors by Total Assets
Key competitors of Larimar Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
USA | $2.25 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
SL Science Holding Limited Ordinary Shares
NASDAQ:SLBT
|
USA | $2.82 Million |
|
REMEGEN CO. LTD YC 1
F:REG
|
Germany | €7.25 Billion |
Larimar Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.29 | 7.48 | 9.63 |
| Quick Ratio | 4.29 | 7.48 | 9.63 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $157.22 Million | $143.35 Million | $66.34 Million |
Larimar Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Larimar Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.37 |
| Latest Market Cap to Assets Ratio | 2.56 |
| Asset Growth Rate (YoY) | -27.2% |
| Total Assets | $145.84 Million |
| Market Capitalization | $373.98 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Larimar Therapeutics Inc's assets at a significant premium (2.56x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Larimar Therapeutics Inc's assets decreased by 27.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Larimar Therapeutics Inc (2012–2025)
The table below shows the annual total assets of Larimar Therapeutics Inc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $145.84 Million | -27.16% |
| 2024-12-31 | $200.22 Million | +108.71% |
| 2023-12-31 | $95.94 Million | -24.11% |
| 2022-12-31 | $126.41 Million | +60.68% |
| 2021-12-31 | $78.67 Million | -24.85% |
| 2020-12-31 | $104.69 Million | +1912.81% |
| 2019-12-31 | $5.20 Million | -95.73% |
| 2018-12-31 | $121.76 Million | +15.40% |
| 2017-12-31 | $105.51 Million | -19.84% |
| 2016-12-31 | $131.62 Million | -30.40% |
| 2015-12-31 | $189.11 Million | +60.92% |
| 2014-12-31 | $117.52 Million | +208.14% |
| 2013-12-31 | $38.14 Million | +247.15% |
| 2012-12-31 | $10.99 Million | -- |
About Larimar Therapeutics Inc
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.